Strateos, Inc. was formed from a merger between Transcriptic and 3Scan. It is Software as a Service (SaaS) based solution provider for biotechnology labs. Strateos automates biology, chemistry, and tissue analysis into robotic labs that fast tracks the process of drug discovery programs. The company leverages technologies like robotics control systems and advanced software for imaging and analytics for accelerating drug discovery process. Strateos console, Elastic chemistry, Biomaker assays, cell-based assays, and biochemical assays are some of the key product offerings of the company.
Scope
- This report provides insights into Strateos, including an overview of the company and its product offering, detailed coverage of its business model and operations, information on its funding and partnerships, and biographies of its senior management
Reasons to Buy
- Gain insights into Strateos' business operations
- Gain insights into its partnerships and funding
- Gain an understanding of its technology focus
Table of Contents
- Overview
- Technology Focus
- Product Overview
- Partnerships & Funding
- Key Employees
- Appendix
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amgen
- Eli Lilly and Company
